Skip to main content
NYSE:PKI

PerkinElmer Stock Forecast, Price & News

$137.86
-1.58 (-1.13 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$137.71
$139.87
50-Day Range
$125.20
$140.97
52-Week Range
$88.60
$162.70
Volume669,634 shs
Average Volume995,005 shs
Market Capitalization$15.45 billion
P/E Ratio37.46
Dividend Yield0.20%
Beta1.19
30 days | 90 days | 365 days | Advanced Chart
Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.


PerkinElmer logo

About PerkinElmer

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
CUSIP71404610
Phone781-663-6900
Employees14,000
Year Founded1931

Sales & Book Value

Annual Sales$2.88 billion
Cash Flow$5.71 per share
Book Value$25.33 per share

Profitability

Net Income$227.56 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap$15.45 billion
Next Earnings Date7/27/2021 (Estimated)
OptionableOptionable

Social Links


MarketRank

Overall MarketRank

1.92 out of 5 stars

Computer And Technology Sector

123rd out of 1,567 stocks

Analytical Instruments Industry

3rd out of 29 stocks

Analyst Opinion: 1.4Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











PerkinElmer (NYSE:PKI) Frequently Asked Questions

Is PerkinElmer a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PerkinElmer stock.
View analyst ratings for PerkinElmer
or view top-rated stocks.

What stocks does MarketBeat like better than PerkinElmer?

Wall Street analysts have given PerkinElmer a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PerkinElmer wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release its next quarterly earnings announcement on Tuesday, July 27th 2021.
View our earnings forecast for PerkinElmer
.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) released its quarterly earnings data on Tuesday, May, 4th. The medical research company reported $3.72 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $3.03 by $0.69. The medical research company earned $1.31 billion during the quarter, compared to analysts' expectations of $1.18 billion. PerkinElmer had a net margin of 12.74% and a trailing twelve-month return on equity of 21.57%. The business's revenue for the quarter was up 100.4% compared to the same quarter last year. During the same period last year, the business earned $0.67 earnings per share.
View PerkinElmer's earnings history
.

How has PerkinElmer's stock been impacted by Coronavirus?

PerkinElmer's stock was trading at $72.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PKI shares have increased by 89.3% and is now trading at $137.86.
View which stocks have been most impacted by COVID-19
.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Thursday, April 29th. Investors of record on Friday, July 16th will be paid a dividend of $0.07 per share on Friday, August 6th. This represents a $0.28 annualized dividend and a dividend yield of 0.20%. The ex-dividend date of this dividend is Thursday, July 15th.
View PerkinElmer's dividend history
.

Is PerkinElmer a good dividend stock?

PerkinElmer pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.20%. PerkinElmer does not yet have a strock track record of dividend growth. The dividend payout ratio of PerkinElmer is 6.83%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PerkinElmer will have a dividend payout ratio of 3.56% next year. This indicates that PerkinElmer will be able to sustain or increase its dividend.
View PerkinElmer's dividend history.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its FY 2021 earnings guidance on Tuesday, May, 11th. The company provided earnings per share guidance of 9.400-9.400 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.670. The company issued revenue guidance of $4.37 billion-$4.37 billion, compared to the consensus revenue estimate of $4.21 billion.

What price target have analysts set for PKI?

9 analysts have issued 12-month target prices for PerkinElmer's stock. Their forecasts range from $45.00 to $193.00. On average, they anticipate PerkinElmer's share price to reach $141.73 in the next year. This suggests a possible upside of 2.8% from the stock's current price.
View analysts' price targets for PerkinElmer
or view top-rated stocks among Wall Street analysts.

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the following people:
  • Dr. Prahlad R. Singh Ph.D., CEO, Pres & Director (Age 56, Pay $4.86M) (LinkedIn Profile)
  • Mr. James M. Mock, Sr. VP & CFO (Age 44, Pay $2.72M)
  • Mr. Tajinder Vohra, Sr. VP of Global Operations (Age 55, Pay $1.4M) (LinkedIn Profile)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 52, Pay $2.44M)
  • Mr. Daniel R. Tereau, Sr. VP of Strategy & Bus. Devel. (Age 53, Pay $1.46M) (LinkedIn Profile)
  • Mr. Andrew Okun, VP, Chief Accounting Officer & Treasurer (Age 51) (LinkedIn Profile)
  • Mr. Bryan Kipp, VP of Investor Relations
  • Mr. Robert Francis Friel, Advisor (Age 65)
  • Ms. Miriame Victor, Sr. VP & Chief Commercial Officer (Age 40) (LinkedIn Profile)
  • Mr. John L. Healy, VP, Associate Gen. Counsel & Assistant Sec.

What is Prahlad Singh's approval rating as PerkinElmer's CEO?

27 employees have rated PerkinElmer CEO Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among PerkinElmer's employees.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), The Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.05%), Geode Capital Management LLC (1.76%), King Luther Capital Management Corp (1.21%), Ceredex Value Advisors LLC (1.12%), Northern Trust Corp (1.09%) and The Manufacturers Life Insurance Company (1.04%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Pascale Witz, Peter Barrett and Prahlad R Singh.
View institutional ownership trends for PerkinElmer
.

Which major investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including King Luther Capital Management Corp, Assenagon Asset Management S.A., Acadian Asset Management LLC, KBC Group NV, JPMorgan Chase & Co., Standard Life Aberdeen plc, Russell Investments Group Ltd., and Sector Gamma AS. Company insiders that have sold PerkinElmer company stock in the last year include Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Peter Barrett, and Prahlad R Singh.
View insider buying and selling activity for PerkinElmer
or view top insider-selling stocks.

Which major investors are buying PerkinElmer stock?

PKI stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Robeco Schweiz AG, Robeco Institutional Asset Management B.V., Alta Capital Management LLC, Grimes & Company Inc., Principal Financial Group Inc., The Manufacturers Life Insurance Company , and AdvisorShares Investments LLC.
View insider buying and selling activity for PerkinElmer
or or view top insider-buying stocks.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $137.86.

How much money does PerkinElmer make?

PerkinElmer has a market capitalization of $15.45 billion and generates $2.88 billion in revenue each year. The medical research company earns $227.56 million in net income (profit) each year or $4.10 on an earnings per share basis.

How many employees does PerkinElmer have?

PerkinElmer employs 14,000 workers across the globe.

Does PerkinElmer have any subsidiaries?

The following companies are subsidiares of PerkinElmer: Analytica of Branford, Applied Biosystems, Arnel Inc., ArtusLabs, Beijing Huaan Magnech Bio-Tech Co. Ltd., Beijing Longrun Bio-Tech Co. Ltd., Beijing Meizheng Bio-Tech Co. Ltd., Beijing Meizheng Testing Lab Co. Ltd., Beijing OUMENG Biotechnology Co. Ltd., Bio Evolution SAS, Bioo Scientific Corporation, Biosense Picolabs Inc., Biosense Technologies Pvt Ltd., Caliper Life Sciences, Caliper Life Sciences Inc., Cambridge Research & Instrumentation Inc., CambridgeSoft, Ceiba Solutions, Chengdu PerkinElmer Medical Laboratory Co. Ltd., Chromo G.A. SAS, CisBio US Inc., Cisbio Asia Pacific Ltd, Cisbio Bioassays SAS, Cisbio China Ltd., Cisbio Group SAS, Cisbio KK, Cisbio.com, DNA Laboratories Sdn. Bhd., Dani Analitica S.r.l., Dexela, EUROIMMUN (Hangzhou) Medical Laboratory Diagnostics Co. Ltd., EUROIMMUN (South East Asia) Pte Ltd., EUROIMMUN (Tianjin) Medical Diagnostic Technology Co. Ltd., EUROIMMUN AG, EUROIMMUN Brasil Medicina Diagnóstica Ltda., EUROIMMUN Diagnostics España S.L.U., EUROIMMUN France SAS, EUROIMMUN Italia Diagnostica Medica S.r.l., EUROIMMUN Japan Co. Ltd., EUROIMMUN Medical Diagnostics (China) Co. Ltd., EUROIMMUN Medical Diagnostics Canada Inc., EUROIMMUN Medical Laboratory Diagnostics South Africa (Pty) Ltd., EUROIMMUN Medizinische Labordiagnostika AG, EUROIMMUN Polska Spólka z o.o., EUROIMMUN Portugal Unipessoal Lda., EUROIMMUN Schweiz AG, EUROIMMUN Turkey Tibbi Laboratuar Teşhisleri A.S., EUROIMMUN UK Ltd., EUROIMMUN US Inc., EUROIMMUN US Real Estate LLC, Geospiza, Guangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Hangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Horizon Discovery, Integromics S.L., Jiangsu Meizheng Bio-Tech Co. Ltd., LabMetrix Technologies, Labtronics, ManCell SAS, NovaScreen Biosciences Corporation, Opto Technology, Orchid Biomedical Systems Pvt Ltd., Oxford Immunotec, Pediatrix Medical Group - Newborn Metabolic Screening Business, Perkin Elmer Chile Ltda., Perkin Elmer Italia SpA, Perkin Elmer Sdn. Bhd., Perkin Elmer Yuhan Hoesa, Perkin Elmer de Mexico S.A., Perkin-Elmer Argentina S.R.L., Perkin-Elmer Instruments (Philippines) Corporation, PerkinElmer (Hong Kong) Ltd., PerkinElmer (India) Pvt Ltd., PerkinElmer (Ireland) Ltd., PerkinElmer (Schweiz) AG, PerkinElmer (Shanghai) Equity Investment Fund L.P., PerkinElmer (Shanghai) Equity Investment Fund Management Co. Ltd., PerkinElmer (UK) Holdings Ltd., PerkinElmer Analytical Solutions B.V., PerkinElmer Automotive Research Inc., PerkinElmer BVBA, PerkinElmer CV Holdings LLC, PerkinElmer Cellular Technologies Germany GmbH, PerkinElmer Danmark A/S, PerkinElmer Diagnostics Global Holdings S.à r.l., PerkinElmer Diagnostics Holdings Inc., PerkinElmer España S.L., PerkinElmer Finance Luxembourg S.à r.l., PerkinElmer Finland Oy, PerkinElmer Genetics Inc., PerkinElmer Germany Diagnostics GmbH, PerkinElmer Global Diagnostics S.à r.l., PerkinElmer Global Financing S.à r.l., PerkinElmer Global Holdings S.à r.l., PerkinElmer Health Sciences (Australia) Pty. Ltd., PerkinElmer Health Sciences B.V., PerkinElmer Health Sciences Canada Inc., PerkinElmer Health Sciences FZ-LLC, PerkinElmer Health Sciences Inc., PerkinElmer Health Sciences Pvt Ltd., PerkinElmer Healthcare Diagnostics (Shanghai) Co. Ltd., PerkinElmer Holding Luxembourg S.à r.l., PerkinElmer Holdings Inc., PerkinElmer Holdings Pty. Ltd., PerkinElmer IVD Pte Ltd., PerkinElmer Inc., PerkinElmer Informatics Inc., PerkinElmer Instruments (Suzhou) Co. Ltd., PerkinElmer International C.V., PerkinElmer Investments Ky, PerkinElmer Israel Ltd., PerkinElmer Japan Co. Ltd., PerkinElmer LAS (Germany) GmbH, PerkinElmer LAS (UK) Ltd., PerkinElmer Life Sciences International Holdings, PerkinElmer Limited, PerkinElmer Ltd., PerkinElmer Management (Shanghai) Co. Ltd., PerkinElmer Nederland B.V., PerkinElmer Norge AS, PerkinElmer Oy, PerkinElmer Polska Sp z o.o., PerkinElmer Pty. Ltd., PerkinElmer SAS, PerkinElmer Sağlık ve Çevre Bilimleri Ltd., PerkinElmer Shared Services Sp z o.o., PerkinElmer Singapore Pte Ltd., PerkinElmer South Africa (Pty) Ltd., PerkinElmer Sverige AB, PerkinElmer Sweden Health Sciences Holdings AB, PerkinElmer Taiwan Corporation, PerkinElmer VertriebsgmbH, PerkinElmer chemagen Technologie GmbH, PerkinElmer do Brasil Ltda., Perten Instruments, Perten Instruments (Beijing) Co. Ltd., Perten Instruments AB, Perten Instruments France SASU, Perten Instruments GmbH, Perten Instruments Italia S.r.l., Perten Instruments of Australia Pty Ltd., RHS Ltd, RayAl Ltd., Shandong Meizheng Bio-Tech Co. Ltd., Shanghai Haoyuan Biotech Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Signature Genomic Laboratories, Solus Scientific Solutions Inc., Solus Scientific Solutions Ltd., Surendra Genetic Labs, Suzhou PerkinElmer Medical Laboratory Co. Ltd., Suzhou Sym-Bio LifeScience, Suzhou Sym-Bio Lifescience Co. Ltd., Tulip Diagnostics, Tulip Diagnostics Pvt Ltd., Vanadis Diagnostics, Vanadis Diagnostics AB, ViaCell, ViaCord LLC, VisEn Medical, VisEn Medical Inc., Wallac Oy, Wellesley B.V., Xenogen Corporation, ZeLab SAS, and chemagen Biopolymer-Technologie AG.

When was PerkinElmer founded?

PerkinElmer was founded in 1931.

What is PerkinElmer's official website?

The official website for PerkinElmer is www.perkinelmer.com.

Where are PerkinElmer's headquarters?

PerkinElmer is headquartered at 940 WINTER STREET, WALTHAM MA, 02451.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.